Harmony Biosciences Holdings, Inc. (HRMY)
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Harmony Biosciences Holdings, Inc.
NASDAQ:HRMYHealthcare · Biotechnology
+1.97%$33.11
CLOSED · Nov 6Prev close$32.47+1.97%Close$33.11-0.33%AH close$33.00
AH$33.00-0.33%vs close
Mkt Cap$1.94B
Float45.73M
O/S58.72M
VOL787K sh
$ Vol$26M
RVOL0.64×
Inst Own96.0%
SI11.8%
Dilution
1-25 of 460 filings
…
Recent SEC filings with analysis
- 10-QHarmony Biosciences reported Q3 2026 net product revenue of $268.9 million, up 12.3% year-over-year, driven by 7.5% unit growth and a 7% price increase.
- 8-KHarmony Biosciences reported Q3 2026 WAKIX net revenue of $268.9 million, up 12% year over year, driven by 400 net patient adds and reiterating full-year…
- 8-KHarmony Biosciences announced a planned CEO succession: Jeffrey M.